Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Myelodysplastic Syndromes 750Leukemia, Myeloid, Acute 635Leukemia 476Leukemia, Myelogenous, Chronic, BCR-ABL Positive 470Precursor Cell Lymphoblastic Leukemia-Lymphoma 409Myeloproliferative Disorders 339Lymphoma, Non-Hodgkin 271Leukemia, Myelomonocytic, Chronic 270Leukemia, Lymphocytic, Chronic, B-Cell 264Multiple Myeloma 259Hodgkin Disease 249Primary Myelofibrosis 230Leukemia, Myeloid, Chronic-Phase 217Lymphoma 203Blast Crisis 195Leukemia, Myeloid, Accelerated Phase 182Lymphoma, Mantle-Cell 168Lymphoma, Follicular 168Burkitt Lymphoma 166Lymphoma, Large B-Cell, Diffuse 162Lymphoma, B-Cell, Marginal Zone 151Congenital Abnormalities 148Polycythemia Vera 144Lymphoma, Large-Cell, Immunoblastic 141Anemia, Refractory, with Excess of Blasts 131Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 128Myelodysplastic-Myeloproliferative Diseases 126Neoplasms, Plasma Cell 117Thrombocythemia, Essential 114Lymphoma, T-Cell, Cutaneous 99

Interventions

ivosidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × IDH1 Mutation Myeloid Neoplasms × Myeloid × Clear all
NCT03564821 2025-11-04

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

Massachusetts General Hospital

Phase 1 Completed
18 enrolled
Myeloid

IDH1 Mutation Myeloid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡